AstraZeneca wagers on $500M buyout, plucks PhIII drug for Alexion’s rare disease pipeline — and jumps straight into risky field
Marc Dunoyer has unveiled his first buyout since taking over at Alexion — one that his predecessors have lassoed in before a $39 billion merger made the rare disease specialist a part of AstraZeneca.
The deal adds another drug to Alexion’s late-stage pipeline, which is heavily populated by candidates sourced through M&A and licensing pacts.
It also takes AstraZeneca into a risky disease that has blown up efforts by Prothena and GlaxoSmithKline.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 124,600+ biopharma pros reading Endpoints daily — and it's free.